share_log

Novavax | 8-K: Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Novavax | 8-K: Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

諾瓦瓦克斯醫藥 | 8-K:Novavax 公佈2024年第一季度財務業績和運營亮點
美股sec公告 ·  05/10 20:09
牛牛AI助理已提取核心訊息
On May 10, 2024, Novavax, Inc. reported its financial results for the first quarter ending March 31, 2024, and announced a significant co-exclusive licensing agreement with Sanofi. The agreement includes a $500 million upfront payment to Novavax, a $70 million equity investment, and potential milestones totaling up to $1.3 billion. Novavax's Q1 2024 revenue reached $94 million, with a reduction in current liabilities by $831 million. The company also announced the removal of its going concern notice and plans to initiate a Phase 3 trial for a COVID-19-Influenza Combination vaccine in the second half of 2024. Novavax's updated financial guidance for 2024 anticipates combined revenue and Sanofi agreement payments between $970 million and $1.17 billion. The company's progress includes the submission of a Biologics License Application for its COVID-19 vaccine to the FDA and the advancement of negotiations for the 2024-2025 vaccination season. Novavax's partnership with Sanofi is expected to drive value creation and benefit global public health by leveraging Novavax's Matrix-M adjuvant technology for the development of new vaccines.
On May 10, 2024, Novavax, Inc. reported its financial results for the first quarter ending March 31, 2024, and announced a significant co-exclusive licensing agreement with Sanofi. The agreement includes a $500 million upfront payment to Novavax, a $70 million equity investment, and potential milestones totaling up to $1.3 billion. Novavax's Q1 2024 revenue reached $94 million, with a reduction in current liabilities by $831 million. The company also announced the removal of its going concern notice and plans to initiate a Phase 3 trial for a COVID-19-Influenza Combination vaccine in the second half of 2024. Novavax's updated financial guidance for 2024 anticipates combined revenue and Sanofi agreement payments between $970 million and $1.17 billion. The company's progress includes the submission of a Biologics License Application for its COVID-19 vaccine to the FDA and the advancement of negotiations for the 2024-2025 vaccination season. Novavax's partnership with Sanofi is expected to drive value creation and benefit global public health by leveraging Novavax's Matrix-M adjuvant technology for the development of new vaccines.
2024年5月10日,Novavax, Inc.公佈了截至2024年3月31日的第一季度財務業績,並宣佈與賽諾菲簽訂一項重要的共同獨家許可協議。該協議包括向Novavax預付5億美元、7000萬美元股權投資以及總額高達13億美元的潛在里程碑。Novavax的2024年第一季度收入達到9400萬美元,流動負債減少了8.31億美元。該公司還宣佈取消其持續經營通知,並計劃在2024年下半年啓動COVID-19流感聯合疫苗的3期試驗。Novavax最新的2024年財務指引預計,收入和賽諾菲協議的總支出在9.7億美元至11.7億美元之間。該公司的進展包括向美國食品藥品管理局提交其 COVID-19 疫苗的生物製劑許可申請,以及推進 2024-2025 年疫苗接種季節的談判。通過利用Novavax的Matrix-M輔助技術開發新疫苗,Novavax與賽諾菲的合作有望推動價值創造並有益於全球公共衛生。
2024年5月10日,Novavax, Inc.公佈了截至2024年3月31日的第一季度財務業績,並宣佈與賽諾菲簽訂一項重要的共同獨家許可協議。該協議包括向Novavax預付5億美元、7000萬美元股權投資以及總額高達13億美元的潛在里程碑。Novavax的2024年第一季度收入達到9400萬美元,流動負債減少了8.31億美元。該公司還宣佈取消其持續經營通知,並計劃在2024年下半年啓動COVID-19流感聯合疫苗的3期試驗。Novavax最新的2024年財務指引預計,收入和賽諾菲協議的總支出在9.7億美元至11.7億美元之間。該公司的進展包括向美國食品藥品管理局提交其 COVID-19 疫苗的生物製劑許可申請,以及推進 2024-2025 年疫苗接種季節的談判。通過利用Novavax的Matrix-M輔助技術開發新疫苗,Novavax與賽諾菲的合作有望推動價值創造並有益於全球公共衛生。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。